Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Tenax Therapeutics (TENX) Operating Expenses (2016 - 2017)

Tenax Therapeutics' Operating Expenses history spans 8 years, with the latest figure at $17.0 million for Q4 2017.

  • For Q4 2017, Operating Expenses fell 74.78% year-over-year to $17.0 million; the TTM value through Dec 2017 reached $9.2 million, down 78.74%, while the annual FY2025 figure was $56.4 million, 189.24% up from the prior year.
  • Operating Expenses for Q4 2017 was $17.0 million at Tenax Therapeutics, up from -$1.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $67.5 million in Q4 2016 and bottomed at -$25.3 million in Q3 2016.
  • The 5-year median for Operating Expenses is $1.8 million (2013), against an average of $6.6 million.
  • The largest YoY upside for Operating Expenses was 94.81% in 2017 against a maximum downside of 161.33% in 2017.
  • A 5-year view of Operating Expenses shows it stood at $1.8 million in 2013, then skyrocketed by 551.14% to $11.8 million in 2014, then tumbled by 47.63% to $6.2 million in 2015, then soared by 991.67% to $67.5 million in 2016, then tumbled by 74.78% to $17.0 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's Operating Expenses are $17.0 million (Q4 2017), -$1.3 million (Q3 2017), and -$3.0 million (Q2 2017).